TGFB1 and neoplasm: The pathway analyses particularly demonstrated CD164’s dual role in promoting oncogenic signaling (PI3K-Akt, TGF-β) while suppressing tumor-suppressive metabolic pathways (AMPK, butyrate metabolism), providing mechanistic insight into its pro-tumorigenic effects.